Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Features

Features
Actin Inhibition: The identification of PTX-2 as a novel anti-mitotic agent that selectively induces apoptosis in p53 deficient cancer cells

18 Aug 05

Although cytotoxics agents represent a cornerstone of oncology, toxicity and drug resistance has driven the development of targeted anticancer therapies. The current study highlights a novel antimitotic agent, PTX-2. This molecule, like the Taxol and Taxotere, blocks the cell cycle in late mitosis channelling cells into an apoptotic program. In direct contrast to Taxol and Taxotere, PTX-2 targets cells with p53 mutations; the plant alkaloids on the other hand are relatively insensitive in such c
LeadDiscovery

Targeting beta-catenin by celecoxib (Celebrex) as an anti-cancer mechanism of action and as a lead for the identification of improved oncology agents

18 Aug 05

Despite the cardiovascular risks that have recently emerged following prolonged treatment with COX-2 inhibitors, this class of drug continues to receive interest as an approach to chemoprevention. Celebrex, which was approved in 1998 for the treatment of familial adenomatous polyposis (FAP) has been shown to reduce the development of precancerous colorectal polyps by 28%. Data recently highlighted in the FASEB journal suggests that at least part of the efficacy of celebrex may be related to the
LeadDiscovery

Selection and Assessment Day

15 Aug 05

Clinical Research Academy has decided to implement a sure-fire way of finding top candidates for Clinical Research Associate (CRA) posts – by running a Selection and Assessment Day. The first was held at the end of July in Marlow in the UK.
Kieran.Engels

Milestone in the development of Histone Deacetylase Inhibitors

05 Aug 05

This alert is brought to you by LeadDiscovery and concerns today's announcement by Celera Genomics that clinical evaluation of their HDAC inhibitor CRA-024781 is about to commence. The press release is featured on today's edition of DailyUpdates-Oncology.
LeadDiscovery

PharmaReports Alert: Pain Therapeutics 2005

03 Aug 05

This PharmaReports alert (29th June, 2005) from LeadDiscovery announces the most recent report of pain to join the company's porfolio of pain reports. This report, Pain Therapeutics, 2005, provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field.
LeadDiscovery

A-425619: A TRPV1 receptor antagonist with potential for the treatment of inflammatory, postoperative and arthritic pain

02 Aug 05

The worldwide analgesic market was worth $38 billion during the year 2002 and is expected to nearly double to $75 billion by the year 2010. The vanilloid receptor TRPV1 (VR1) has become an attractive molecular target for multiple sub-types of pain. Abbott researchers have recently described the development of A-425619
LeadDiscovery

Development stage candidate from Bayer Healthcare for the treatment of traumatic head injury, stroke, Parkinson's disease and Alzheimer' s disease

01 Aug 05

Acute neurodegeneration caused by stroke or trauma as well as more chronic disease resulting from Alzheimers’s disease or Parkinson’s disease has inflammatory and direct neurotoxic components. Bayer Healthcare researchers have developed a compound with anti-inflammatory and neuroprotective active resulting is therapeutic activity in models of head injury and Parkinson’s disease
LeadDiscovery

Taishi's 20-HETE synthesis inhibitor, TS-011 as a candidate acute treatment for hemorrhagic and ishemic stroke

28 Jul 05

Each year, 750,000 strokes occur in the US and resultant deaths account for stroke being one of the top three causes of mortality as well as a major economic burden on healthcare systems. One candidate molecular target for stroke is 20-HETE. Taisho Pharmaceutical have developed a potent and selective 20-HETE synthesis inhibitor, TS-011 for the treatment of stroke.
LeadDiscovery

Working in France

28 Jul 05

Tourists love France and why not you… to work and live in France.
Claire Armstrong i3 Pharma Resourcing

Vanilloid receptor desensitization as a strategy for improving glucose tolerance as well as reducing diabetic neuropathic pain

27 Jul 05

The vanilloid capsaicin has long been known to desensitize pain pathways leading to long-term analgesia. Recent data from Novo Nordisk A/S suggests that sensory afferents might also be implicated in the development of glucose intolerance.
LeadDiscovery

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.